Peripheral artery disease, the ‘lost syndrome’ during lockdown for COVID‑19: A report of three cases

Panzavolta,Chiara; Zalunardo,Beniamino; Irsara,Sandro; Ferretto,Luca; Visonà,Adriana

doi:10.3892/mi.2021.15

Peripheral artery disease, the ‘lost syndrome’ during lockdown for COVID‑19: A report of three cases

Authors:
- Chiara Panzavolta
- Beniamino Zalunardo
- Sandro Irsara
- Luca Ferretto
- Adriana Visonà
View Affiliations

Affiliations: Angiology Unit, Azienda ULSS 2 Marca Trevigiana, Castelfranco Veneto, I-31033 Treviso, Italy, Department of Vascular Surgery, Azienda ULSS 1 Dolomiti, I-32100 Belluno, Italy
Published online on: September 16, 2021 https://doi.org/10.3892/mi.2021.15
Article Number: 15
Copyright: © Panzavolta et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The recent coronavirus disease 2019 (COVID‑19) pandemic has significantly increased the burden placed on healthcare systems worldwide. This health emergency has led to changes being implemented in the organization of health institutions and has shifted the focus on pandemic management. This has led to marked changes being made in the treatment of patients without COVID‑19, and has resulted in more difficult access to healthcare, with ensuing delays in diagnosis and treatment. Vascular diseases, including peripheral artery disease (PAD), require prompt treatment in the majority of cases in order to save affected limbs. Moreover, COVID‑19 may result in acute arterial and venous complications, which need to be promptly recognized and treated. The present study describes three paradigmatic clinical cases of hospitalized patients, which are representative of the different forms of the ‘lost syndrome’ caused by either the direct effect of COVID‑19 or by the effects of COVID‑19 on the healthcare system and lifestyle factors. Prophylaxis against arterial and venous thrombotic events is crucial in patients with COVID‑19, particularly those with a marked inflammatory state. On the other hand, the COVID‑19 pandemic has diminished the access to healthcare system for patients with other chronic pathologies, with potential severe consequences for vulnerable patient groups, such as those with PAD and cardiovascular diseases. For these patients, the authors' experience over the last few months suggests that more suitable measures need to be adopted to avoid additional severe consequences on public health. In addition, it is necessary to identify pathways that will allow these patients to have rapid access to treatment with marked improvements in outcome.

View Figures

View References

1	Ge H, Wang X, Yuan X, Xiao G, Wang C, Deng T, Yuan Q and Xiao X: The epidemiology and clinical information about COVID-19. Eur J Clin Microbiol Infect Dis. 39:1011–1019. 2020.PubMed/NCBI View Article : Google Scholar
2	Zarocostas J: What next for the coronavirus response? Lancet. 395(401)2020.PubMed/NCBI View Article : Google Scholar
3	Schuivens PME, Buijs M, Boonman-de Winter L, Veen EJ, de Groot HGW, Buimer TG, Ho GH and van der Laan L: Impact of the COVID-19 lockdown strategy on vascular surgery Practice: More major amputation than usual. Ann Vasc Surg. 69:74–79. 2020.PubMed/NCBI View Article : Google Scholar
4	Tang N, Bai H, Chen X, Gong J, Li D and Sun Z: Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 18:1094–1099. 2020.PubMed/NCBI View Article : Google Scholar
5	Mohammad M, Safavi-Naeini P, Solomon SD and Vardeny O: Potential effects of coronavirus on the cardiovascular system a review. JAMA Cardiol. 5:831–840. 2020.PubMed/NCBI View Article : Google Scholar
6	Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 395:497–506. 2020.PubMed/NCBI View Article : Google Scholar
7	Gonzalez Cañas E, Gimenez Gaibar A, Rodriguez Lorenzo L, Castro Rios JG, Martinez Toiran M, Bella Cueto MR, Bella Burgos B and Espasa Soley M: Acute peripheral arterial thrombosis in COVID-19. Role of endothelial inflammation. Br J Surg. 107:e444–e445. 2020.PubMed/NCBI View Article : Google Scholar
8	Mehta P, McAuley DF, Brown M, Sanchez E, Tattersal RS and Manson JJ: HLH Across Speciality Collaboration, UK. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet. 395:1033–1034. 2020.PubMed/NCBI View Article : Google Scholar
9	Rogers MAM, Levine DA, Blumberg N, Flanders SA, Chopra V and Langa KM: Triggers of hospitalization for venous thromboembolism. Circulation. 125:2092–2099. 2012.PubMed/NCBI View Article : Google Scholar
10	Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, Huisman MV, Humbert M, Jennings CS, Jiménez D, et al: 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS). Eur Heart J. 41:543–603. 2020.PubMed/NCBI View Article : Google Scholar
11	Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson CG, Turpie AG and Weisslinger N: A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 341:793–800. 1999.PubMed/NCBI View Article : Google Scholar
12	Leizorovicz A, Cohen AT, Turpie AGG, Olsson CG, Vaitkus PT and Goldhaber SZ: PREVENT Medical Thromboprophylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 10:874–879. 2004.PubMed/NCBI View Article : Google Scholar
13	Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, Turpie AGG, Egberts JFM and Lensing AWA: ARTEMIS Investigators. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: Randomized placebo controlled trial. BMJ. 332:325–329. 2006.PubMed/NCBI View Article : Google Scholar
14	Schünemann HJ, Cushman M, Burnett AE, Kahn SR, Beyer-Westendorf J, Spencer FA, Rezende SM, Zakai NA, Bauer KA, Dentali F, et al: American society of hematology 2018 guidelines for management of venous thromboembolism: Prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv. 2:3198–3225. 2018.PubMed/NCBI View Article : Google Scholar
15	Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, Cook DJ, Balekian AA, Klein RC, Le H, et al: Prevention of VTE in nonsurgical patients: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 141 (Suppl 2):e195S–e226S. 2012.PubMed/NCBI View Article : Google Scholar
16	Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, Nigoghossian C, Ageno W, Madjid M, Guo Y, et al: COVID-19 and thrombotic or thromboembolic disease: Implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol. 75:2950–2973. 2020.PubMed/NCBI View Article : Google Scholar
17	Hunt BJ: Hemostasis at extremes of body weight. Semin Thromb Hemost. 44:632–639. 2018.PubMed/NCBI View Article : Google Scholar
18	World Health Organization (WHO): Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: Interim guidance, 28 January 2020. WHO, Geneva, 2020.
19	Ho KM and Tan JA: Stratified meta-analysis of intermittent pneumatic compression of the lower limbs to prevent venous thromboembolism in hospitalized patients. Circulation. 128:1003–1020. 2013.PubMed/NCBI View Article : Google Scholar
20	Spyropoulos AC, Lipardi C, Xu J, Peluso C, Spiro TE, De Sanctis Y, Barnathan ES and Raskob GE: Modified IMPROVE VTE risk score and elevated D-dimer identify a high venous thromboembolism risk in acutely Ill medical population for extended thromboprophylaxis. TH Open. 4:e59–e65. 2020.PubMed/NCBI View Article : Google Scholar
21	Spyropoulos AC, Lipardi C, Xu J, Lu W, Suh E, Yuan Z, Levitan B, Sugarmann C, De Sanctis Y, Spiro TE, et al: Improved benefit risk profile of rivaroxaban in a subpopulation of the MAGELLAN study. Clin Appl Thromb Hemost. 25(1076029619886022)2019.PubMed/NCBI View Article : Google Scholar
22	Cohen AT, Spiro TE, Spyropoulos AC, Desanctis YH, Homering M, Büller HR, Haskell L, Hu D, Hull R, Mebazaa A, et al: D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: A subanalysis of the randomized controlled MAGELLAN trial. J Thromb Haemost. 12:479–487. 2014.PubMed/NCBI View Article : Google Scholar
23	Gerotziafas GT, Catalano M, Colgan MP, Pecsvarady Z, Wautrecht JC, Fazeli B, Olinic DM, Farkas K, Elalamy I, Falanga A, et al: Guidance for the management of patients with vascular disease or cardiovascular risk factors and COVID-19: Position paper from VAS-European independent foundation in angiology/vascular medicine. Thromb Haemost. 120:1597–1628. 2020.PubMed/NCBI View Article : Google Scholar
24	Sena G and Gallelli G: An increased severity of peripheral arterial disease in the COVID-19 era. J Vasc Surg. 72(758)2020.PubMed/NCBI View Article : Google Scholar
25	Chiesa R, Kahlberg A, Rinaldi E and Mascia D: Emergency management of the COVID-19 pandemic in a vascular surgery department of a large metropolitan hospital in Italy. Preparation, escalation, de-escalation, and normal activity. J Card Surg. 36:1632–1636. 2021.PubMed/NCBI View Article : Google Scholar